

Average Proteinuria Grade Combined SLE Experiments +/- SEM




FIGURE 1

Dosing Protocol













SLE-5	Treatment, 3x/wk, Subcutaneously	Age (weeks)																	
		25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40		
A	5 mg/kg Rapamycin (AY-22989-21)																		
B	200 ug/ms anti-murine B7.1																		
	200 ug/ms anti-murine B7.2																		
C	5 mg/kg Rapamycin (AY-22989-21)																		
	200 ug/ms anti-murine B7.1																		
	200 ug/ms anti-murine B7.2																		
D	5 mg/kg Rapamycin (AY-22989-21)																		
E	5 mg/kg Rapamycin (AY-22989-21)																		
	200 ug/ms anti-murine B7.1																		
	200 ug/ms anti-murine B7.2																		
F	200 ug/ms anti-murine IL-12																		
G	Vehicle																		

FIGURE 2

97 JPS-002 SLE-7 Histopathologic Evaluation of NZB x NZW F1 Hybrid Female Mice

42 weeks of age

Group	Animal	Spleen	Spleen	Kidney	Kidney	Kidney
No Therapy		Lymphoid Hyperplasia	Hematopoiesis	Interstitial Inflammation	Glomerulonephritis Cellularity- Membrane Thickness	Tubular Dilatation
	1	- 2	- 3	+ 2	- 2	+ 2
	2	+ 2	+ 2	+ 3	- 1	+ 3
	3	+ 2	+ 2	+ 2	- 1	+ 3
	4	+ 2	+ 2	+ 3	- 3	+ 3
	5	+ 2	+ 3	+ 3	- 3	+ 3
	Mean	+ 1.2	+ 1.2	+ 2.6	- 2.0	+ 2.8

Rapamycin
(Treatment Weeks 29-36)

1	+ 1	+ 1	(+ 1)	0	+ 1	+ 1
2	+ 1	+ 1	(+ 1)	0	+ 1	0
3	+ 1	+ 1	(+ 2)	0	0	0
4	+ 1	+ 1	0	0	0	0
5	+ 1	+ 1	(+ 1)	0	0	0
Mean	+ 1.0	+ 1.0	+ 1.0	0	+0.4	+ 0.2

Histologic Grades

- 0 = Normal
- 1 = Slight
- 2 = Mild
- 3 = Moderate
- 4 = Marked
- 5 = Severe
- () = Focal not Diffuse

Histopathologic Assessment : Elizabeth Goad, PhD, DVM.

FIGURE 3




FIGURE 4A




FIGURE 4B

A.

Single Therapeutic Dosing




FIGURE 5A

B.

Combined Therapeutic Dosing




FIGURE 5B